Published in Br J Haematol on September 01, 1994
The molecular detection of circulating tumour cells. Br J Cancer (1995) 1.55
Assessment of IgH PCR strategies in multiple myeloma. J Clin Pathol (1996) 0.86
Detection of clonal immunoglobulin gene rearrangements in the peripheral blood progenitor cells of patients with multiple myeloma: the potential role of purging with CD34 positive selection. Clin Mol Pathol (1996) 0.78
Peripheral blood stem cell transplants. J Clin Pathol (1998) 0.77
A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature (1996) 27.61
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med (2013) 8.89
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med (2013) 6.67
Mechanisms of evolution in Rickettsia conorii and R. prowazekii. Science (2001) 5.32
Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. Nat Genet (1999) 4.74
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia (2008) 3.58
Simple, rapid method for assay of aminoglycoside antibiotics. Lancet (1971) 3.35
The complete genome sequence of the murine respiratory pathogen Mycoplasma pulmonis. Nucleic Acids Res (2001) 2.75
A human homologue of the Drosophila eyes absent gene underlies branchio-oto-renal (BOR) syndrome and identifies a novel gene family. Nat Genet (1997) 2.68
The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia (2006) 2.49
Interleukin-1 beta-modulated gene expression in immortalized human chondrocytes. J Clin Invest (1994) 2.42
Spectrum of SPG4 mutations in autosomal dominant spastic paraplegia. Hum Mol Genet (2000) 2.40
Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol (1997) 2.14
Health and functional status of long-term survivors of bone marrow transplantation. EBMT Working Party on Late Effects and EULEP Study Group on Late Effects. European Group for Blood and Marrow Transplantation. Ann Intern Med (1997) 1.93
Long-term expression of human adenosine deaminase in mice transplanted with retrovirus-infected hematopoietic stem cells. Proc Natl Acad Sci U S A (1989) 1.91
Inhibition of autophagy abrogates tumour necrosis factor alpha induced apoptosis in human T-lymphoblastic leukaemic cells. Br J Haematol (1997) 1.87
Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood (2000) 1.84
Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia (2003) 1.84
Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet (2003) 1.80
Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet (2001) 1.76
Pre-induction LDH as a prognostic factor for outcome of high dose chemotherapy (HDCT) for germ cell tumours relapsing or refractory to conventional chemotherapy. Br J Cancer (2000) 1.74
Mental calculation in a prodigy is sustained by right prefrontal and medial temporal areas. Nat Neurosci (2001) 1.70
hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. Leukemia (2010) 1.67
Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology (1994) 1.65
Ocular toxicity of high-dose intravenous desferrioxamine. Lancet (1983) 1.63
Clustering of mutations responsible for branchio-oto-renal (BOR) syndrome in the eyes absent homologous region (eyaHR) of EYA1. Hum Mol Genet (1997) 1.59
Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med (1999) 1.59
Perlecan, the major proteoglycan of basement membranes, is altered in patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia). Nat Genet (2000) 1.58
Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) (2006) 1.53
Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. Leukemia (2007) 1.53
Intraoperative ventricular puncture. Neurosurgery (1988) 1.51
HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Chronic Leukemia Working Party of the European Blood and Marrow Transplant Registry. Leukemia (2000) 1.49
CD34 counts to predict the adequate collection of peripheral blood progenitor cells. Bone Marrow Transplant (1997) 1.48
Stem cell mobilization in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide. Br J Haematol (1997) 1.48
Arteriovenous malformations of the brain: choosing embolic materials to enhance safety and ease of excision. J Neurosurg (1992) 1.47
Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor) Blood (1995) 1.43
Intensive treatment of renal failure in patients with myeloma. Clin Lab Haematol (1994) 1.43
Triple arthrodesis for diabetic peritalar neuroarthropathy. Foot Ankle Int (1995) 1.43
Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD) Bone Marrow Transplant (1999) 1.42
G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. Br J Haematol (1997) 1.42
Technetium (99mTc)-labelled white cell scanning, 51Cr-EDTA and 14C-mannitol-labelled intestinal permeability studies: non-invasive methods of diagnosing acute intestinal graft-versus-host disease. Bone Marrow Transplant (1994) 1.41
Economic evaluation of peripheral blood stem cell transplantation for lymphoma. Lancet (1992) 1.40
Is it refractory idiopathic thrombocytopenic purpura? Lancet (1997) 1.39
Treatment of erythropoietin resistance with cyclosporin. Lancet (1994) 1.38
The erythropoietic response to erythropoietin in patients with rheumatoid arthritis. J Lab Clin Med (1997) 1.38
Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol (2001) 1.36
High-dose intravenous IgG in adults with autoimmune thrombocytopenia. Lancet (1983) 1.34
Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med (1986) 1.33
Rapid Identification of Mycobacterium tuberculosis and nontuberculous mycobacteria by multiplex, real-time PCR. J Clin Microbiol (2009) 1.32
Effect on primary Rh immunization of delayed administration of anti-Rh. Immunology (1975) 1.30
Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (1998) 1.30
Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles. Leukemia (2009) 1.29
Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood (2000) 1.27
A combined frontotemporal and lateral infratemporal fossa approach to the skull base. J Neurosurg (1988) 1.24
Peripheral blood stem cells as an alternative to marrow for allogeneic transplantation. Lancet (1993) 1.24
Late-onset hemorrhagic cystitis associated with urinary excretion of polyomaviruses after bone marrow transplantation. Transplantation (1987) 1.23
Erythrapheresis in patients with polycythaemia secondary to hypoxic lung disease. Br Med J (Clin Res Ed) (1983) 1.23
Treatment of dural sinus thrombosis using selective catheterization and urokinase. Ann Neurol (1995) 1.22
Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy (2001) 1.22
Wound-healing technologies: low-level laser and vacuum-assisted closure. Evid Rep Technol Assess (Summ) (2004) 1.21
CCNU (lomustine), idarubicin and dexamethasone (CIDEX): an effective oral regimen for the treatment of refractory or relapsed myeloma. Br J Haematol (2000) 1.21
Pulmonary aspergillosis in patients with leukaemia. J Clin Pathol (1990) 1.20
Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia (2005) 1.19
Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. Blood (1999) 1.18
Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant (1986) 1.17
Intravenous ciprofloxacin in the treatment of infection in immunocompromised patients. J Antimicrob Chemother (1986) 1.17
Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant (2010) 1.16
Long-term clinical results of autologous infusion of mobilized adult bone marrow derived CD34+ cells in patients with chronic liver disease. Cell Prolif (2008) 1.16
Severe aplastic anaemia after parvovirus infection in the absence of underlying haemolytic anaemia. J Clin Pathol (1988) 1.15
T cell receptor gene rearrangements define a monoclonal T cell proliferation in patients with T cell lymphocytosis and cytopenia. Blood (1986) 1.15
Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant (2006) 1.14
Apaf-1 protein deficiency confers resistance to cytochrome c-dependent apoptosis in human leukemic cells. Blood (2001) 1.13
Immunopharmacology of the superantigen staphylococcal enterotoxin A in T-cell receptor V beta 3 transgenic mice. Immunology (1993) 1.13
Phenotypic and molecular analysis of six human cell lines derived from patients with plasma cell dyscrasia. Br J Haematol (1999) 1.13
LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre. Bone Marrow Transplant (2006) 1.12
Treatment of the Guillain-Barré syndrome by plasma exchange. J Neurol Neurosurg Psychiatry (1982) 1.11
Intraoperative aneurysmal rupture: incidence, outcome, and suggestions for surgical management. Neurosurgery (1986) 1.11
Cutaneous reactions in relation to the use of 'TED'-stockings. Lancet (1989) 1.10
Comparison of EDTA and EDDS as potential soil amendments for enhanced phytoextraction of heavy metals. Chemosphere (2005) 1.10
Lymphocyte subsets in subjects exposed to asbestos: changes in circulating natural killer cells. Br J Ind Med (1992) 1.10
Management of infection in the neutropenic patient. Br Med J (Clin Res Ed) (1986) 1.10
Microsatellite instability occurs in defined subsets of patients with acute myeloblastic leukaemia. Br J Haematol (2001) 1.10
Chronic T cell lymphocytosis: a review of 21 cases. Br J Haematol (1984) 1.10
Ranking of laboratory tests by consensus analysis. Lancet (1986) 1.09